Author

Ayrea E. Hurley

Baylor College of MedicineORCID 0000-0002-8697-8610Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:CRISPR screen· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Gang BaoiD· 2 shared William R. LagoriD· 2 shared Adam B. Castoreno· 1 shared Alexandria M. DoerfleriD· 1 shared Buhle MoyoiD· 1 shared Christine BeetoniD· 1 shared Christopher J. WalkeyiD· 1 shared David T. CurieliD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Gang BaoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene

Marco De Giorgi, So Hyun Park, Adam B. Castoreno, Mingming Cao, Ayrea E. Hurley, Lavanya Saxena, Marcel A. Chuecos, Christopher J. Walkey, Alexandria M. Doerfler, Mia N. Furgurson, M. Cecilia Ljungberg, Kalyani R. Patel, Sarah Hyde, Tyler Chickering, Stephanie Lefebvre, , William R. Lagor

This paper introduces a method to increase the proportion of correctly repaired hepatocytes in the liver through transient gene inhibition and transgene delivery, achieving a 25% increase in targeted cells and five-fold transgene expression.

Science Translational Medicine · Feb 12, 2025Peer-reviewedGenetics

Covalently linked adenovirus-AAV complexes as a novel platform technology for gene therapy

Logan Thrasher Collins, Wandy L. Beatty, Paul Boucher, Buhle Moyo, Michele Alves‐Bezerra, Ayrea E. Hurley, William R. Lagor, Gang Bao, David T. Curiel, Zhi Hong Lu

This paper introduces a novel gene therapy platform using covalently linked adenovirus-AAV complexes to improve co-infection efficiency and reduce AAV dose requirements.

bioRxiv · Aug 21, 2024 · PreprintSynthetic Biology